Holen Sie sich die Stockscreener-App
202.41
0.01%
-0.03
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$202.44
Offen:
$204.36
24-Stunden-Volumen:
642.02K
Relative Volume:
0.61
Marktkapitalisierung:
$22.31B
Einnahmen:
$10.52B
Nettoeinkommen (Verlust:
$999.00M
KGV:
24.20
EPS:
8.3628
Netto-Cashflow:
$1.22B
1W Leistung:
-2.16%
1M Leistung:
+7.12%
6M Leistung:
+9.77%
1J Leistung:
+17.58%
1-Tages-Spanne:
$200.94
$204.41
1-Wochen-Bereich:
$200.94
$208.93
52-Wochen-Spanne:
$157.20
$213.20
Quest Diagnostics Inc Stock (DGX) Company Profile
Firmenname
Quest Diagnostics Inc
Sektor
Branche
Telefon
(973) 520-2700
Adresse
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
202.41 | 22.32B | 10.52B | 999.00M | 1.22B | 8.3628 |
|
TMO
Thermo Fisher Scientific Inc
|
510.93 | 193.53B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
209.50 | 149.33B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
635.66 | 50.36B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
122.90 | 35.73B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
333.33 | 32.24B | 3.17B | 642.63M | 539.81M | 10.77 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-08-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-01-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | Jefferies | Buy |
| 2024-10-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Fortgesetzt | Evercore ISI | In-line |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-02-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-29 | Eingeleitet | Piper Sandler | Neutral |
| 2023-05-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-23 | Eingeleitet | Evercore ISI | In-line |
| 2022-11-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-23 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-02 | Herabstufung | Jefferies | Buy → Hold |
| 2022-01-28 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-03-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Hochstufung | Argus | Hold → Buy |
| 2020-07-29 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-09 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-04-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2019-04-02 | Hochstufung | Jefferies | Hold → Buy |
| 2019-03-18 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-01-31 | Herabstufung | Argus | Buy → Hold |
| 2019-01-17 | Eingeleitet | UBS | Neutral |
| 2019-01-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Quest Diagnostics Inc Aktie (DGX) Neueste Nachrichten
Quest Diagnostics (NYSE:DGX) SVP Sells $196,227.14 in Stock - MarketBeat
Quest Diagnostics (NYSE:DGX) EVP Sells $293,521.39 in Stock - MarketBeat
Insider Selling: Quest Diagnostics (NYSE:DGX) SVP Sells 1,111 Shares of Stock - MarketBeat
A diagnostics company moved out. Its former landlord claims it left a mess. - The Business Journals
Quest Diagnostics Incorporated $DGX Stock Holdings Boosted by Vanguard Group Inc. - MarketBeat
First National Bank of Omaha Invests $8.83 Million in Quest Diagnostics Incorporated $DGX - MarketBeat
Advisors Capital Management LLC Acquires 14,258 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Skandinaviska Enskilda Banken AB publ Sells 27,243 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Piper Sandler Adjusts Price Target on Quest Diagnostics to $215 From $200, Maintains Neutral Rating - marketscreener.com
Do Wall Street Analysts Like Quest Diagnostics Stock? - Barchart.com
5 Insightful Analyst Questions From Quest's Q4 Earnings Call - Finviz
Cibc World Market Inc. Increases Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
M&G PLC Has $208.26 Million Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated $DGX Shares Sold by ABN Amro Investment Solutions - MarketBeat
Rhumbline Advisers Decreases Stock Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
ING Groep NV Makes New Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
Wall Street Recap: What analysts say about Quest Diagnostics Incorporated stock - baoquankhu1.vn
A Look At Quest Diagnostics (DGX) Valuation After Strong Results, 2026 Outlook, Buybacks And New Myeloma Test - Yahoo Finance
Quest Diagnostics (NYSE:DGX) Has Announced That It Will Be Increasing Its Dividend To $0.86 - Yahoo Finance
Quest Diagnostics Incorporated $DGX Shares Sold by Cookson Peirce & Co. Inc. - MarketBeat
Quest Diagnostics (DGX): Analyst Raises Price Target to $235 | D - GuruFocus
Mizuho Securities Adjusts Quest Diagnostics PT to $235 From $210, Maintains Outperform Rating - marketscreener.com
Rothschild & Co Redburn Adjusts Quest Diagnostics PT to $224 From $200, Maintains Buy Rating - marketscreener.com
Forecasting The Future: 6 Analyst Projections For Quest Diagnostics - Benzinga
DGX Q4 Deep Dive: Consumer Testing and Advanced Diagnostics Fuel Growth Amid Margin Headwinds - Finviz
Quest Diagnostics (DGX): Truist Securities Raises Price Target A - GuruFocus
UBS Raises Price Target for Quest Diagnostics (DGX) to $210 | DG - GuruFocus
Deutsche Bank Adjusts Quest Diagnostics Price Target to $205 From $178, Maintains Hold Rating - marketscreener.com
DGX: Evercore ISI Group Raises Price Target for Quest Diagnostics | DGX Stock News - GuruFocus
Quest Diagnostics (DGX): Navigating the New Frontier of Advanced Diagnostics and AI Efficiency - FinancialContent
Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Evercore ISI Adjusts Quest Diagnostics PT to $220 From $190, Maintains In Line Rating - marketscreener.com
Barclays Adjusts Quest Diagnostics PT to $225 From $210, Maintains Overweight Rating - marketscreener.com
Baird Adjusts Quest Diagnostics Price Target to $219 From $203, Maintains Neutral Rating - marketscreener.com
Quest Diagnostics Incorporated (NYSE:DGX) Q4 2025 Earnings Call Transcript - Insider Monkey
DGX: Jefferies Raises Target Price for Quest Diagnostics to $220 - GuruFocus
Truist Raises Price Target on Quest Diagnostics to $220 From $205, Keeps Hold Rating - marketscreener.com
Candriam S.C.A. Has $13.69 Million Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Shares Jump on Q4 Beat; FY25 Revenue Rises, 2026 Outlook Raised - AlphaStreet News
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MSN
Quest Diagnostics Q4 Earnings Call Highlights - Yahoo Finance
Jefferies Maintains Buy on Quest Diagnostics (DGX) Feb 10, 2026 - Meyka
Quest Diagnostics: Q4 Earnings Snapshot - theheraldreview.com
Why Is Quest (DGX) Stock Soaring Today - Finviz
Quest Diagnostics (DGX) Earnings Call Transcript - The Globe and Mail
Quest Diagnostics Inc (DGX) Q4 2025 Earnings Call Highlights: St - GuruFocus
Quest Diagnostics hits 52-week high as outlook tops consensus - MSN
Why Is Quest Diagnostics Stock Soaring Tuesday?Quest Diagnostics (NYSE:DGX) - Benzinga
Quest's (NYSE:DGX) Q4 CY2025: Beats On Revenue - Finviz
Quest Diagnostics' Q4 Earnings & Revenues Beat Estimates, Stock Up - sharewise.com
Quest Diagnostics (DGX) Sees Significant Stock Price Surge - GuruFocus
Finanzdaten der Quest Diagnostics Inc-Aktie (DGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.07%
2.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):